DGAP-News: CO.DON AG
/ Key word(s): Miscellaneous
10.02.2020 / 11:55
The issuer is solely responsible for the content of this announcement.
CO.DON AG adds contract manufacturing to its product portfolio
Berlin / Teltow / Leipzig, 10 February 2020 – CO.DON AG now also offers contract manufacturing services for human cells. In addition to its product for the autologous treatment of cartilage defects in the knee joint, its portfolio has now been expanded to include cell cultivation services for third party providers. The first partner for the new business segment is MukoCell GmbH,a company that offers a advanced therapy medicinal product made from autologous oral mucosa cells. The undersigned contract includes the production of the pharmaceutical product at the Leipzig site. In the past two years this has seen the construction of one of the world’s largest and most modern plants for the industrial-scale production of human cells.
“We are looking forward to this collaboration which brings benefits for both parties. We repeatedly received enquiries about the availability of CO.DON’s new site for contract manufacturing. We are proud to be able to offer customers the use of our technology for routine production, to cover capacity peaks, bridge initial phases or carry out research projects with GMP and non-GMP material. Customers will have the benefit of using this technology without having to invest in manufacturing equipment.”, explains Tilmann Bur, Executive Board of CO.DON AG. “Contract manufacturing allows us to generate additional income that will further boost revenue for CO.DON AG.”
CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient’s own cartilage cells (“autologous chondrocytes”). CO.DON’s method is currently used in over 200 clinics in Germany and more than 15,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). At the Leipzig site, CO.DON has built one of the world’s largest and most modern facilities for the production of human cells on an industrial scale for in-house and contract manufacturing. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Tilmann Bur.
Further information is available from www.codon.de.
10.02.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||971583|
|End of News||DGAP News Service|